RCT is an early-stage research and development company developing healthcare solutions based on Stem Cells, Extracellular Vesicles (EVs) and Immune Cells.
RCT’s mission is to build a pipeline-driven platform technology development of cell based therapy for the treatment of serious, life-threatening diseases where there are limited treatment options for patients.
RCT’s research programs are centered on three interconnected pillars, forming the foundation of our platform-driven approach to cell-based therapies.
We explore the regenerative and reparative properties of stem cells to restore damaged tissues and organs. Our work emphasizes:
Extracellular Vesicles are emerging as powerful, cell-free therapeutic tools. RCT investigates EVs for their role in:
Our immune cell research focuses on harnessing and enhancing the body’s natural defense mechanisms to fight disease. Key areas include:
RCT follows a platform-driven development model, enabling us to:
This approach allows efficient translation of early research into robust preclinical programs and future clinical pipelines.
Our research is directed toward serious and life-threatening conditions where current treatment options are limited or ineffective, including:
Each program is designed with a strong focus on safety, efficacy, and translational potential.
Scientific integrity and patient safety are at the core of our research philosophy. RCT emphasizes rigorous experimental design, compliance with global quality standards, and ethical advancement of cell-based technologies.
RCT’s research aims to create transformational therapies that address the underlying mechanisms of disease. By combining cutting-edge science with disciplined development, we strive to improve patient outcomes and quality of life worldwide.